Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Isabelle Martel-Laffay"'
Autor:
Isabelle Martel-Laffay, Alain Vergnenegre, Radj Gervais, Paul Lesueur, Christos Chouaid, Alexandre Escande, Roland Schott, M. Kissel, Chrystel Locher
Publikováno v:
Expert Review of Anticancer Therapy. 18:1159-1165
Cisplatin-based chemotherapy administered concomitantly to thoracic radiotherapy is the treatment recommended by the European guidelines for fit patients with unresectable stage III non-small cell lung cancer (NSCLC). Cisplatin may be combined with e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e42503b9aff35ae844c5353b650b352
https://doi.org/10.1080/14737140.2018.1518714
https://doi.org/10.1080/14737140.2018.1518714
Autor:
Jean-Pierre Gérard, David Azria, Sophie Gourgou-Bourgade, Isabelle Martel-Laffay, Christophe Hennequin, Pierre-Luc Etienne, Véronique Vendrely, Eric François, Guy de La Roche, Olivier Bouché, Xavier Mirabel, Bernard Denis, Laurent Mineur, Jean-François Berdah, Marc André Mahé, Yves Bécouarn, Olivier Dupuis, Gérard Lledo, Christine Montoto-Grillot, Thierry Conroy
Publikováno v:
Journal of Clinical Oncology. 28:1638-1644
Purpose Neoadjuvant chemoradiotherapy is considered a standard approach for T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified radiotherapy plus capecitabine and oxaliplatin. Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0faf8993d944c63beb7cb52e2e7a98a7
https://doi.org/10.1200/jco.2009.25.8376
https://doi.org/10.1200/jco.2009.25.8376
Autor:
Christophe Hennequin, E. Francois, T. Conroy, Véronique Vendrely, C. Montoto-Grillot, D. Azria, P.L. Etienne, Isabelle Martel-Laffay, Sophie Gourgou-Bourgade, Jean-Pierre Gerard
Publikováno v:
Journal of Clinical Oncology. 27:LBA4007-LBA4007
LBA4007 Background: Following the results of randomized trials FFCD 9203 and EORTC 2291, neoadjuvant CT-RT is considered standard treatment for LARC. The ACCORD 12/0405 PRODIGE 2 trial was initiated to optimize this regimen. Methods: Pts with T3 or r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fba737ba69a1c80a796aa77c8e57ca8
https://doi.org/10.1200/jco.2009.27.18_suppl.lba4007
https://doi.org/10.1200/jco.2009.27.18_suppl.lba4007